Last reviewed · How we verify

NCT06340945

The Outcomes of Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules

Recruiting now NA Last updated 19 March 2026
What this trial tests

NA trial testing ultrasound-guided thermal ablation in Thyroid Nodules in 1,500 participants. Currently enrolling.

Timeline
1 April 2024
Primary endpoint
31 December 2027
31 December 2029

Quick facts

Lead sponsorChinese PLA General Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsequential
Maskingnone
Primary purposetreatment
Enrollment1,500
Start date1 April 2024
Primary completion31 December 2027
Estimated completion31 December 2029
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Chinese PLA General Hospital

Who can join

18 and older, any sex, with Thyroid Nodules. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. To evaluate the clinical outcomes of ultrasound-guided thermal ablationfor the treatment of benign thyroid nodules; 2. To develop and validate a artificial intelligence model to predict the outcomes of ultrasound-guided thermal ablation in the treatment of benign thyroid nodules

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of ultrasound-guided thermal ablation

Trials testing the same drug.

Other recruiting trials for Thyroid Nodules

Currently open trials in the same condition.

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06340945.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing